on October 19, 2007
Published online before print October 19, 2007, doi: 10.1161/ATVBAHA.107.141606
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 19, 2007
Accepted on September 19, 2007
The Haemostatic Role of Tissue Factor Pathway Inhibitor
James T.B. Crawley * and David A. Lane
From the Department of Hematology, Imperial College London, UK.
* To whom correspondence should be addressed. E-mail: j.crawley{at}imperial.ac.uk.
Abstract—Under normal conditions the blood circulates freely within the confines of the vascular system, carrying oxygen, nutrients, and hormonal information around the body and removing metabolic waste. If blood gains access to extravascular sites, or the vasculature becomes pathologically challenged, hemostasis may be activated. This process is finely regulated by positive and negative feedback loops that modulate fibrin clot formation. Blood coagulation revolves around the activation and assembly of the components of the prothrombinase complex, which converts the inactive zymogen, prothrombin, into its active form, thrombin. This serine protease catalyzes the conversion of fibrinogen to fibrin, the structural scaffold that stabilizes platelet aggregates at sites of vascular injury. The extent of the hemostatic response is controlled by the action of inhibitory pathways, which ensure that thrombin activity and the spread of the hemostatic plug is limited to the site of vessel damage. This review article focuses on the major physiological regulator of tissue factor–induced coagulation, tissue factor pathway inhibitor, its expression, anticoagulant function, and its role in normal hemostasis.
Key words: TFPI • anticoagulant • tissue factor • thrombosis • hemostasis
Related Article:
- Adding Complexity to Fibronectin-Platelet Interactions
- Deane F. Mosher
Arterioscler Thromb Vasc Biol 2008 28: 203-204.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
 |
|
 |
|
  M. Delvaeye and E. M. Conway Coagulation and innate immune responses: can we view them separately? Blood, September 17, 2009; 114(12): 2367 - 2374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Zhang, J. G. Berrocal, K. M. Frizzell, M. J. Gamble, M. E. DuMond, R. Krishnakumar, T. Yang, A. A. Sauve, and W. L. Kraus Enzymes in the NAD+ Salvage Pathway Regulate SIRT1 Activity at Target Gene Promoters J. Biol. Chem., July 24, 2009; 284(30): 20408 - 20417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Xu, M. L. Previti, M. T. Nieman, J. Davis, A. H. Schmaier, and W. E. Van Nostrand A{beta}PP/APLP2 Family of Kunitz Serine Proteinase Inhibitors Regulate Cerebral Thrombosis J. Neurosci., April 29, 2009; 29(17): 5666 - 5670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Duckers, P. Simioni, L. Spiezia, C. Radu, S. Gavasso, J. Rosing, and E. Castoldi Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency Blood, November 1, 2008; 112(9): 3615 - 3623. [Abstract] [Full Text] [PDF]
|
|